Stock Track | Mind Medicine (MindMed) Soars 5.38% as Evercore ISI Maintains Buy Rating

Stock Track11-10

Shares of Mind Medicine (MindMed) Inc. (MNMD) are soaring 5.38% in pre-market trading on Monday, following a positive analyst report from Evercore ISI. The surge comes as investors react to the reiterated Buy rating and the ambitious price target set for the psychedelic medicine company.

Evercore ISI analyst maintained their bullish stance on Mind Medicine, setting a price target of $23.00 for the stock. This vote of confidence from a respected Wall Street firm has evidently sparked renewed interest in MNMD shares. The price target suggests significant upside potential, which is likely contributing to the stock's strong performance in early trading.

Mind Medicine, a company at the forefront of developing psychedelic-inspired medicines and therapies, has been attracting attention in the biotechnology sector. The positive analyst coverage comes at a time when there's growing interest in alternative treatments for mental health conditions. As the market opens, investors will be watching closely to see if MNMD can maintain its momentum throughout the trading session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1122210431?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 22:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122210431","market":"sg","top_or_hot":-1,"title":"Stock Track | Mind Medicine (MindMed) Soars 5.38% as Evercore ISI Maintains Buy Rating","media":"Stock Track","content":"<p>Shares of Mind Medicine (MindMed) Inc. (MNMD) are soaring 5.38% in pre-market trading on Monday, following a positive analyst report from Evercore ISI. The surge comes as investors react to the reiterated Buy rating and the ambitious price target set for the psychedelic medicine company.</p>\n\n<p>Evercore ISI analyst maintained their bullish stance on Mind Medicine, setting a price target of $23.00 for the stock. This vote of confidence from a respected Wall Street firm has evidently sparked renewed interest in MNMD shares. The price target suggests significant upside potential, which is likely contributing to the stock's strong performance in early trading.</p>\n\n<p>Mind Medicine, a company at the forefront of developing psychedelic-inspired medicines and therapies, has been attracting attention in the biotechnology sector. The positive analyst coverage comes at a time when there's growing interest in alternative treatments for mental health conditions. As the market opens, investors will be watching closely to see if MNMD can maintain its momentum throughout the trading session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Mind Medicine (MindMed) Soars 5.38% as Evercore ISI Maintains Buy Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Mind Medicine (MindMed) Soars 5.38% as Evercore ISI Maintains Buy Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-10 22:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Mind Medicine (MindMed) Inc. (MNMD) are soaring 5.38% in pre-market trading on Monday, following a positive analyst report from Evercore ISI. The surge comes as investors react to the reiterated Buy rating and the ambitious price target set for the psychedelic medicine company.</p>\n\n<p>Evercore ISI analyst maintained their bullish stance on Mind Medicine, setting a price target of $23.00 for the stock. This vote of confidence from a respected Wall Street firm has evidently sparked renewed interest in MNMD shares. The price target suggests significant upside potential, which is likely contributing to the stock's strong performance in early trading.</p>\n\n<p>Mind Medicine, a company at the forefront of developing psychedelic-inspired medicines and therapies, has been attracting attention in the biotechnology sector. The positive analyst coverage comes at a time when there's growing interest in alternative treatments for mental health conditions. As the market opens, investors will be watching closely to see if MNMD can maintain its momentum throughout the trading session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNMD","symbol_name":"Mind Medicine (MindMed) Inc.","start_time":0,"source_url":"","article_id":"1122210431","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122210431","pubTimestamp":1762785904,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Mind Medicine (MindMed) Inc. (MNMD) are soaring 5.38% in pre-market trading on Monday, following a positive analyst report from Evercore ISI. The surge comes as investors react to the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MNMD":"Mind Medicine (MindMed) Inc."},"translate_title":"个股追踪|Mind Medicine(MindMed)大涨5.38%Evercore ISI维持买入评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNMD":1},"content_text":"Shares of Mind Medicine (MindMed) Inc. (MNMD) are soaring 5.38% in pre-market trading on Monday, following a positive analyst report from Evercore ISI. The surge comes as investors react to the reiterated Buy rating and the ambitious price target set for the psychedelic medicine company.\nEvercore ISI analyst maintained their bullish stance on Mind Medicine, setting a price target of $23.00 for the stock. This vote of confidence from a respected Wall Street firm has evidently sparked renewed interest in MNMD shares. The price target suggests significant upside potential, which is likely contributing to the stock's strong performance in early trading.\nMind Medicine, a company at the forefront of developing psychedelic-inspired medicines and therapies, has been attracting attention in the biotechnology sector. The positive analyst coverage comes at a time when there's growing interest in alternative treatments for mental health conditions. As the market opens, investors will be watching closely to see if MNMD can maintain its momentum throughout the trading session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122210431","isCrawlerRequest":true}